ALPMY - Astellas Pharma Inc.
| Previous Close | 17.26 |
| Open | 16.83 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 16.83 - 17.13 |
| 52 Week Range | 12.41 - 17.50 |
| Volume | 20,006 |
| Avg. Volume | 64,107 |
| Market Cap | 32B |
| Beta (3Y Monthly) | 0.83 |
| PE Ratio (TTM) | 20.00 |
| EPS (TTM) | 0.85 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.37 (2.12%) |
| Ex-Dividend Date | 2019-09-26 |
| 1y Target Est | N/A |
- Moody's
Astellas Pharma Inc. -- Moody's reviews Astellas Pharma's A1 ratings for downgrade
Moody's Japan K.K. has placed Astellas Pharma Inc.'s A1 issuer ratings under review for downgrade. The rating action follows Astellas' announcement on 3 December 2019 that it had entered into a definitive agreement to acquire the entire stock of Audentes Therapeutics, Inc. for approximately USD3 billion. "This acquisition indicates an urgency for Astellas to feed its long term product pipeline after a wave of patent expiries this year, and signals a rise in acquisition event risk," says Akifumi Fukushi, a Moody's Vice President and Senior Analyst.
- GuruFocus.com
Astellas-Audentes Deal Likely to Ignite More Acquisitions
Companies with gene therapy capabilities are becoming more attractive to members of Big Pharma, who are eager to add the technology to their portfolios Continue reading...
- PR Newswire
Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science
Astellas Venture Management (President: Shunichiro Matsumoto, Ph.D., MBA, "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), and Mission Bay Capital BioLabs ("MBC BioLabs"), a life-science incubator, today announced AmbAgon Therapeutics and Gordian Biotechnology as the winners of the Astellas-sponsored "Golden Ticket Competition." The award supports advancing early-stage companies' pre-clinical scientific discoveries, reflecting Astellas' ongoing commitment to discovering and advancing innovative science for the potential future benefit of patients worldwide.
- PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Audentes Therapeutics, Inc. ("Audentes" or the "Company") (NASDAQ: BOLD) in connection with the proposed acquisition of the Company by Astellas Pharma Inc. ("Astellas Pharma") (OTC:ALPMY). Under the terms of the acquisition agreement, BOLD shareholders will receive $60.00 per share in cash.
- Investor's Business Daily
This Gene Therapy Stock Just Netted A $3 Billion Bid — Who's Next?
Shares of Audentes Therapeutics rocketed more than 100% Tuesday on news Japanese pharmaceutical company Astellas Pharma will acquire the gene therapy biotech company for $3 billion.
- MarketWatch
Astellas’ $3 billion gene therapy deal steadies investors after stalled Roche acquisition
Astellas Pharma Inc.’s $3 billion acquisition of Audentes Therapeutics is a strong indicator that the pharmaceutical industry’s march into gene therapy development isn’t going to slow down in 2020.
- Benzinga
Japan's Astellas To Buy Gene Therapy Company Audentes For $3B Cash
Astellas and Audentes Therapeutics Inc (NASDAQ: BOLD) said they have entered a definitive agreement for the former to acquire the latter for $60 per share in cash, representing a total equity value of about $3 billion. The per-share transaction value represents a 110% premium to Audentes' Monday closing price of $28.61. Astellas, through Asilomar, an acquisition vehicle of its U.S. subsidiary, will commence in the next few weeks a tender offer to buy all outstanding Audentes shares.
- Barrons.com
Gene-Therapy Firm Audentes Sells for Double Its Share Price. It Could Be the First of Many More Deals.
Astellas Pharma is paying $60 a share in cash for a gene-therapy stock that closed at $28.61 on Monday.
- MarketWatch
Astellas bets $3 billion in gene therapy deal
Shares of Astellas Pharma Inc. rose about 1% in premarket trading after the Japanese drugmaker said Monday evening that it plans to acquire Audentes Therapeutics for $3 billion in cash. Audentes is developing gene therapies. Its stock jumped 105% in premarket trading. "This is just another bullish domino for genetic medicine," Raymond James' Steven Seedhouse wrote in a research note. In recent years, there have been a number of high-profile buyouts of companies developing gene therapies, including Roche's $4.8 billion pending acquisition of Spark Therapeutics and Novartis's $8.7 billion purchase of AveXis. Astellas said the boards of both companies have approved the deal. Shares of Astellas have gained 35% year-to-date, while the S&P 500 is up about 24%.
- Benzinga
The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
- TheStreet.com
[video]Audentes Therapeutics Soars on Astellas Pharma's $3 Billion Purchase
Astellas Pharma says it's going to buy the clinical stage biotech company for $3 billion in cash.
- PR Newswire
Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the presentation of new data in acute myeloid leukemia (AML) at the 61st American Society of Hematology (ASH) Annual Meeting, taking place Dec. 7-10 in Orlando, Fla.
- PR Newswire
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through a subsidiary, to evaluate the combination of Seattle Genetics' and Astellas' antibody-drug conjugate (ADC) enfortumab vedotin and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with previously untreated metastatic urothelial cancer.
- Benzinga
The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
- PR Newswire
Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA)
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the China National Medical Products Administration (NMPA) approved a new drug application (NDA) for XTANDI® (enzalutamide) on November 18 for the treatment of adult men with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) in whom chemotherapy is not yet clinically indicated.
- PR Newswire
Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics
TOKYO and COLUMBIA, Md., Nov. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas" ) and Welldoc, Inc. (President, CEO: Kevin McRaith, "Welldoc") today announced that the companies have entered into a collaboration and license agreement directed toward the development and commercialization of digital health solutions. Under the agreement, Astellas and Welldoc will jointly develop and commercialize BlueStar®(1) in Japan and certain other Asian markets for patients with diabetes, collaborate to broaden the adoption of BlueStar® in the U.S. market, and jointly develop and commercialize digital therapeutics in other therapeutic areas globally.
- PR Newswire
New England Journal of Medicine Publishes Results from Astellas' Phase 3 ADMIRAL Trial of XOSPATA® (gilteritinib) in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia(1)
- Results were published online and in the October 31 print edition of the Journal - TOKYO , Oct. 31, 2019 /PRNewswire/ -- The New England Journal of Medicine published detailed results from the Phase ...
- PR Newswire
U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney Injury
TOKYO, Oct. 28, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of ASP1128 for patients at increased risk of developing moderate to severe acute kidney injury (AKI) after coronary artery bypass and/or valve (CABG/V) surgery. The Fast Track designation is intended to facilitate the development, and expedite the FDA review, of drugs to treat serious and life-threatening conditions so that, if approved, the compounds can reach the market more expeditiously.
- Benzinga
The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise ...
- PR Newswire
European Commission Approves Astellas' XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Approval follows accelerated assessment, orphan designation by European Medicines Agency TOKYO , Oct. 25, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., ...
- Moody's
Astellas Pharma Inc. -- Moody's announces completion of a periodic review of ratings of Astellas Pharma Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Astellas Pharma Inc. Tokyo, October 17, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Astellas Pharma Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- PR Newswire
Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy
TOKYO, Oct. 1, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced it will invest nearly $13 million into two innovation incubators operated by LabCentral, a premier United States-based laboratory facility for next-generation biotech start-ups. This initiative, combined with the more than $1 billion Astellas has previously committed to driving innovation in Massachusetts, contributes to the Boston-area life science community's ongoing efforts to accelerate the discovery and development of potential breakthrough therapies in areas of significant unmet need.
- PR Newswire
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer
BOTHELL, Wash. and TOKYO, Sept. 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced initial results from the phase 1 clinical trial EV-103. Forty-five patients were evaluated for safety with the combination of the investigational agent enfortumab vedotin and the immune therapy pembrolizumab in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for treatment with cisplatin-based chemotherapy.
- GuruFocus.com
Investors May Want to Follow the Progress of These Biotechs
Companies recognized by key industry publication for innovative approaches Continue reading...
- PR Newswire
Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years(1) TOKYO , Sept. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: ...
